Introduction
============

Major changes have occurred in the standard management of the axilla in patients with invasive breast cancer, with standard treatment progressing from axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB). Intraoperative pathologic evaluation of sentinel lymph nodes (SLNs) has changed surgical practice and has the advantage that it allows patients with positive SLNs to avoid reoperation by immediately proceeding to ALND.

Recently reported results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial indicate that complete ALND does not improve survival in women with clinical T1-T2 tumors and one or two involved axillary nodes who are undergoing lumpectomy with radiation therapy followed by systemic therapy \[[@b1-crt-2016-473]\]. Thus, a significant proportion of these patients may not require ALND, reducing the usefulness of intraoperative pathologic assessment \[[@b2-crt-2016-473]\]. However, intraoperative evaluation of SLN is highly effective at detecting the subgroup of patients who may benefit from ALND during the same surgical procedure \[[@b3-crt-2016-473]\].

Advances in preoperative imaging have further changed the algorithm for axillary management. Preoperative knowledge of axillary lymph node (ALN) involvement has improved individualized multidisciplinary treatment options \[[@b4-crt-2016-473]\]. In this study, we investigated whether preoperative imaging and clinicopathological factors could be used to identify patients with high tumor burden in ALNs, thus allowing the selection of patients requiring intraoperative analysis of SLNs. Based on preoperative imaging and clinicopathological factors, we also sought to develop a nomogram for use in clinical practice that would predict the probability of the involvement of three or more ALNs.

Materials and Methods
=====================

The Seoul National University Hospital Breast Care Center Database (SNUHBCC database) \[[@b5-crt-2016-473]\] was reviewed to identify patients with clinical T1-T2 invasive breast cancer and clinically negative ALNs who underwent surgery at Seoul National University Hospital (SNUH) between January 2006 and December 2011. Detailed information regarding the SNUHBCC database that was prospectively collected after obtaining institutional review board approval has been reported \[[@b5-crt-2016-473]\]. For this study, 1,917 consecutive patients who underwent surgery between 2006 and 2010 were considered the training set, whereas the 378 patients who underwent surgery in 2011 were considered the validation set. Patients with a previous history of breast cancer, with palpable ALNs, with *in situ* cancer on preoperative core biopsy, who received neo-adjuvant chemotherapy, with tumors \> 5 cm on preoperative ultrasonography (US), or with stage IV breast cancer were excluded from both sets. Following validation and development of a nomogram, the latter was applied prospectively to 512 patients with invasive breast cancer who met the selection criteria of the ACOSOG Z0011 trial and were candidates for breast conserving surgery between January 2012 and June 2014.

1. Preoperative imaging
-----------------------

US, contrast-enhanced chest computed tomography (CT), and positron emission tomography (PET)--CT were conducted for preoperative staging of the axilla and distant organs. All images were reviewed by specialized radiologists who had been informed that the patients had invasive breast cancer.

Axillary US examination was performed 1 day before surgery. The maximum cortical thickness was measured on a cross-sectional plane perpendicular to the long axis of the lymph node \[[@b6-crt-2016-473]\]. The probability of lymph node metastasis was classified by US according to the maximum thickness of the cortex and the appearance of fatty hilum. Grades 1-3 were defined as cortical thicknesses of ≤ 1.5 mm; \> 1.5 mm but ≤ 2.5 mm; and \> 2.5 mm but ≤ 3.5 mm, respectively; grade 4 as cortical thickness \> 3.5 mm with an intact fatty hilum; and grade 5 as cortical thickness \> 3.5 mm with loss of the fatty hilum.

All included patients underwent preoperative CT using the protocol described for asymptomatic lung and liver metastases \[[@b7-crt-2016-473]\]. Chest CT in patients with breast cancer was designed to cover the entire liver, the thoracic cavity and both axilla. ALNs were considered tumor-positive if their shortest diameter was \> 1 cm, there was loss of fatty hilum, and/or central necrosis was present.

Of the 1,917 patients in the training set, 364 (19.1%) were evaluated by fluorodeoxyglucose (FDG) PET-CT. Standard uptake values were calculated from the amount of FDG injected, body weight, and soft tissue uptake in attenuation-corrected regional images.

2. Management of ALNs
---------------------

The SLNB technique, in which SLNs are detected using a radioisotope technique and/or with a blue dye, has been described previously \[[@b8-crt-2016-473]\]. Briefly, 1 to 6 hours prior to surgery Tc-99m antimony sulfur colloid (0.4 mCi) was intradermally injected into the quadrant containing the tumor, lymphoscintigraphic images were obtained approximately 40 minutes later and SLNs were intraoperatively detected using a gamma probe (NEO2000, Neoprobe Co., Dublin, OH). Four areas around the areola were injected intradermally with 0.8% indigo carmine (1 mL) dye immediately before surgery. SLNs were identified as any nodes with radioactive counts ≥ 10% higher than that of the most radioactive node and/or those stained blue. SLNs and grossly enlarged non-SLNs suspicious for metastasis were harvested, with most bisected and examined intraoperatively by hematoxylin and eosin staining of frozen sections. Postoperatively, SLNs were formalin-fixed, paraffin-embedded, and sectioned in 4-μm thickness for pathologic examination. Training and validation set patients with positive SLNBs underwent complete level I and level II ALND.

3. Statistical analysis
-----------------------

The associations between having ≥ 3 involved ALNs with patient demographic characteristics, tumor characteristics on preoperative biopsy, and preoperative imaging results were evaluated by Fisher exact tests. Multivariate logistic regression analysis was conducted using a combination of continuous variables (age, tumor size on preoperative US, and ultrasonographic ALN classification) and dichotomized variables (finding suspicious of positive ALN on chest CT). A nomogram predicting the probability of involvement of ≥ 3 ALNs was then developed based on the multivariate logistic regression model, with a forward stepwise selection method and likelihood-ratio test used to select a subset of all analyzed factors.

The performance of the nomogram was evaluated by receiver operating characteristic (ROC) curve analysis, with calculation of the areas under the ROC curves. The nomogram was calibrated by plotting the observed probability against the predicted probability from the nomogram. A perfectly accurate nomogram prediction model would result in a plot in which the observed and predicted probabilities would fall along a 45° line. Thus, the distance between the pairs and the 45° line is a measure of the absolute error of prediction of the nomogram \[[@b9-crt-2016-473]\]. All statistical analyses were performed using SPSS ver. 19.0 (SPSS Inc., Chicago, IL) and the R Software ver. 2.10.0 (<http://www.r-project.org/>). A p \< 0.05 was considered statistically significant.

Results
=======

Patients, tumors, treatments, and preoperative image characteristics are shown in [Table 1](#t1-crt-2016-473){ref-type="table"}. The mean age at diagnosis was 50.5 years (range, 24 to 85 years). Of the 1,917 patients in the training set, 204 (10.7%) showed involvement of ≥ 3 ALNs, and 427 (22.3%) underwent ALND. The mean number of retrieved SLNs was 3.44±1.2 (range, 1 to 9).

Chest CT showed findings suspicious of ALN involvement in 198 patients (10.3%). PET-CT was performed in 364 patients (19.9%), among which 105 (28.8%) had findings suspicious of ALN involvement.

1. Risk factors of having three or more involved nodes
------------------------------------------------------

Univariate logistic regression analysis ([Table 2](#t2-crt-2016-473){ref-type="table"}) showed that having three or more involved ALNs was significantly associated with tumor size on preoperative US (p \< 0.001), ultrasonographic ALN classification (p \< 0.001), and findings suspicious of positive ALN on chest CT (p \< 0.001) and PET-CT (p \< 0.001), while it was marginally associated with patient age (p=0.053).

[Table 3](#t3-crt-2016-473){ref-type="table"} shows the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of US, CT, and PET-CT in predicting involvement of ≥ 3 ALNs. Multivariate logistic regression analysis was performed using patient age, tumor size on preoperative US (cm), ultrasonographic ALN classification, findings suspicious of positive ALN on chest CT, and findings suspicious of positive ALN on PET-CT. Higher grade ultrasonographic ALN classification (odds ratio \[OR\], 2.13; 95% confidence interval \[CI\], 1.80 to 2.52; p \< 0.001) and findings suspicious of positive ALN on chest CT (OR, 4.78; 95% CI 3.07 to 7.45; p \< 0.001) were found to be independent predictors of having ≥ 3 involved ALNs. However, findings suspicious of positive ALN on PET-CT were no longer significant (p=0.163).

Since only 27.3% of the patients in the training set underwent PET-CT, another multivariate logistic regression analysis was performed excluding the PET-CT findings ([Table 4](#t4-crt-2016-473){ref-type="table"}). This analysis showed that higher grade ultrasonographic ALN classification (p \< 0.001) and findings suspicious of positive ALN on chest CT (p \< 0.001) were significantly and independently correlated with an increased probability of having ≥ 3 involved ALNs.

2. Nomogram development and validation
--------------------------------------

The results of the multivariate analysis were used to develop a nomogram predicting the likelihood of involvement of ≥ 3 positive ALNs for use in clinical practice. Points were assigned to each variable, such as patient age at diagnosis, axillary US grade, and positive ALN findings on chest CT, then summed to yield the total number of points. The latter was used to assign a probability of ≥ 3 positive ALNs for individual patients using the scale at the bottom of [Fig. 1](#f1-crt-2016-473){ref-type="fig"}. The areas under the ROC curves were 0.852 (95% CI, 0.820 to 0.883) for the training set and 0.896 (95% CI, 0.836 to 0.957) for the validation set ([Fig. 2](#f2-crt-2016-473){ref-type="fig"}).

To assess the accuracy of the nomogram, the actual probability was plotted against the calculated predicted probability of having ≥ 3 involved ALNs for each patient in the external validation set ([Fig. 3](#f3-crt-2016-473){ref-type="fig"}). The overall predictive accuracy of the model was within a margin of error of 10%.

The specificity and NPV of the nomogram were calculated and the ability of the nomogram to correctly classify patients into two groups (those with ≤ 2 or ≥ 3 involved ALNs) was determined based on whether the predicted probability was more or less than 40%. When using ≤ 123 points as a cut-off, the specificity of the nomogram was 90% and its NPV was 95.8%. Of the 1,610 patients in the training set predicted to have ≤ 2 involved ALNs, only 68 (4.2%) showed false-negative results, resulting in a reoperation rate of ALND \< 5%. Thus, this cut-off could be used to define a subset of patients that could avoid intraoperative frozen analysis. Use of the same cut-off in the validation set of 378 patients showed that 307 (81.2%) had ≤ 2 involved ALNs, of which only seven (2.3%) showed false-negative results (i.e., ≥ 3 involved ALNs).

3. Prospective application of the nomogram
------------------------------------------

The nomogram was subsequently applied to a prospective cohort of 512 patients ([S1 Table](#SD1-crt-2016-473){ref-type="supplementary-material"}). Of these, 452 patients (88.3%) had nomogram scores below the cut-off and could avoid intraoperative frozen analysis of SLNs. Thus, the costs of frozen biopsy and operation time could be reduced (data not shown). Of the patients with a low score and without frozen biopsy, only eight (1.6% of all 512 patients) had ≥ 3 involved SLNs and required reoperation for complete ALND ([S2 Table](#SD2-crt-2016-473){ref-type="supplementary-material"}). However, without applying the nomogram, 22 patients (4.3%) would have undergone reoperation.

Discussion
==========

The effectiveness of intraoperative evaluation of SLN biopsy remains unclear \[[@b10-crt-2016-473]-[@b12-crt-2016-473]\]. This method is used to identify patients with metastatic SLNs during the primary surgery, enabling them to avoid a possible second operation. However, the examination rate of intraoperative frozen sections of SLN has been declining \[[@b13-crt-2016-473]\] for several reasons. First, the yield of the frozen section procedure is generally low, and it is even lower for certain low-risk patients. For example, when used to evaluate women aged ≥ 60 years with T1a, b tumors only 3%-8% are found to be positive by frozen biopsies \[[@b14-crt-2016-473]\]. Additionally, a review of currently available data revealed that the false-negative rate of intraoperative frozen sections of SLN was 14%-43% \[[@b15-crt-2016-473]-[@b21-crt-2016-473]\]. Moreover, patients with positive frozen biopsies of SLN who undergo immediate ALND may require reoperation, many for tumorinvolved resection margins \[[@b22-crt-2016-473]\]. Finally, the ACOSOG Z0011 trial found that a significant proportion of patients, including women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, one to two sentinel LNs containing metastases, and scheduled for whole breast radiation and systemic therapy, may not require ALND at all.

Predicting ALN status prior to surgery can facilitate surgical planning and informed discussions with patients regarding management options. Various nonsurgical methods including US, CT scan, PET imaging, and magnetic resonance imaging have been tried to predict lymph node involvement \[[@b23-crt-2016-473]-[@b29-crt-2016-473]\]; however, their predictive accuracies were not high enough to replace SLN biopsy. A previous study conducted by our group revealed that US classification of ALN showed 85% sensitivity and 78% specificity for predicting metastasis, with an area under the curve of 0.861 (95% CI, 0.796 to 0.926) \[[@b6-crt-2016-473]\]. A recent review of 21 studies of preoperative US-guided needle biopsy reported a median sensitivity of 64% and a median specificity of 82% \[[@b30-crt-2016-473]\].

We hypothesized that, although it would be difficult to distinguish involvement of zero and at least one LN, it may be possible to predict high LN tumor burden, which was defined as involvement of ≥ 3 ALNs. Preoperative imaging was able to predict patients with ≥ 3 positive ALNs, enabling the avoidance of intraoperative analysis of SLNs in patients with low scores on the nomogram, thereby reducing operation times and costs. Using this method, the rate of reoperation was very low.

Findings suspicious of metastatic ALN on chest CT were a significant predictor of high tumor burden in the axilla, making chest CT results a major component of our nomogram. This is one of the limitations of this study, since chest CT is not a routinely performed imaging modality for early stage breast cancer patients in most institutions. However, our findings indicate the necessity of performing chest CT to use our nomogram in practice. In contrast to a small study of 35 breast cancer patients, which reported that chest CT had a low NPV (20%) for axillary metastases \[[@b26-crt-2016-473]\], we found a high NPV of 93.9% and a specificity of 92.8% for predicting ≥ 3 metastatic ALNs.

PET-CT has been utilized more frequently than chest CT to evaluate ALN metastasis. In our study, PET-CT had a low PPV (27.2%) and was not significant in multivariate analysis (p=0.163). This may have been due to the relatively low percentage (19.9%) of our patients evaluated by PET-CT. Further investigations are required to determine whether adding PET-CT to our nomogram would enhance its performance.

Two strategies are deemed feasible for patients who meet the criteria of the ACOSOG Z0011 trial: to never or always evaluate intraoperative frozen biopsy samples. Use of our nomogram could reduce the reoperation rate when compared with the non-use of frozen biopsy, while saving time and costs compared with universal use of frozen biopsy.

It should be noted that this model had several limitations in addition to those associated with the use of chest CT. Specifically, US classification of ALN may be subjective and has not been validated in other institutions.

In summary, we showed that patients with a high probability of having ≥ 3 positive ALNs can be identified using preoperative imaging methods, such as CT and US, as well as patient demographic and clinical characteristics. The developed nomogram may be useful for identifying patients who do not require intraoperative analysis of SLNs.
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###### 

Patient characteristics of the training set

  Characteristic                           No. (%) (n=1,917)
  ---------------------------------------- -------------------
  **Age (yr)**                             
   Mean±SD                                 50.5±10.2
   Range                                   24-85
  **Tumor size by preoperative US (cm)**   
   Mean±SD                                 2.28±1.02
   Range                                   0.4-5
  **Axillary LN involvement**              
   ≤ 2                                     1,713 (89.4)
   ≥ 3                                     204 (10.6)
  **Axillary US classification**           
   1                                       657 (34.3)
   2                                       694 (36.2)
   3                                       292 (15.2)
   4                                       159 (8.3)
   5                                       105 (5.5)
   Unknown                                 10 (0.5)
  **Chest CT ALN**                         
   Positive                                198 (10.3)
   Negative                                1,716 (89.5)
   Unknown                                 3 (0.2)
  **PET-CT ALN**                           
   Positive                                105 (5.5)
   Negative                                259 (13.5)
   Unknown                                 1,553 (81.0)
  **Surgery-breast**                       
   Conservation                            1,368 (71.4)
   Mastectomy                              549 (28.6)
  **Surgery-axilla**                       
   Sentinel LN biopsy only                 1,490 (77.7)
   ALND                                    427 (22.3)
  **Pathology**                            
   Ductal                                  1,776 (92.6)
   Lobular                                 71 (3.7)
   Other                                   70 (3.7)
  **Pathologic tumor size (cm)**           
   ≤ 2                                     1,079 (56.3)
   \> 2                                    838 (43.7)
  **Estrogen receptor**                    
   Positive                                1,355 (70.7)
   Negative                                542 (28.3)
   Unknown                                 20 (1.0)
  **Progesterone receptor**                
   Positive                                1,116 (58.2)
   Negative                                785 (40.9)
   Unknown                                 16 (0.9)
  **HER2 receptor**                        
   Positive                                257 (13.4)
   Negative                                1,600 (83.5)
   Unknown                                 60 (3.1)

US, ultrasonography; LN, lymph node; CT, computed tomography; ALN, axillary lymph node; PET, positron emission tomography; ALND, axillary lymph node dissection; HER2, human epidermal growth factor receptor 2.

###### 

Factors associated with involvement of three or more ALNs

  Variable                                 Three or more LN (+) (%)   Two or less LN (+) (%)   p-value
  ---------------------------------------- -------------------------- ------------------------ ----------
  **Age (yr)**                             49.2                       50.6                     0.053
  **Tumor size by preoperative US (cm)**   2.66±1.07                  2.23±1.0                 \< 0.001
  **Tumor size by MRI (cm)**               2.86±1.58                  2.17±1.46                \< 0.001
  **US tumor size (cm)**                                                                       
   ≤ 2                                     68 (33.3)                  851 (49.7)               \< 0.001
   \> 2-5                                  136 (66.7)                 862 (50.3)               
  **Axillary US classification**                                                               
   Gr 1                                    11 (5.4)                   646 (37.7)               \< 0.001
   Gr 2                                    34 (16.7)                  660 (38.5)               
   Gr 3                                    38 (18.6)                  254 (14.8)               
   Gr 4                                    57 (27.9)                  102 (6.0)                
   Gr 5                                    62 (30.4)                  43 (2.5)                 
  **Chest CT ALN**                                                                             
   Positive                                106 (52.7)                 92 (5.4)                 \< 0.001
   Negative                                95 (47.3)                  1,621 (94.6)             
  **PET-CT ALN**                                                                               
   Positive                                34 (79.1)                  71 (22.1)                \< 0.001
   Negative                                9 (20.9)                   250 (77.9)               
  **Estrogen receptor**                                                                        
   Positive                                134 (67.3)                 1,221 (71.9)             0.177
   Negative                                65 (32.7)                  477 (28.1)               
  **Progesterone receptor**                                                                    
   Positive                                125 (62.2)                 991 (58.3)               0.289
   Negative                                76 (37.8)                  709 (41.7)               
  **HER2 receptor**                                                                            
   Positive                                34 (17.0)                  223 (13.5)               0.171
   Negative                                166 (83.0)                 1,434 (86.5)             

Values are presented as mean±standard deviation or number (%). ALN, axillary lymph node; LN, lymph node; US, ultrasonography; MRI, magnetic resonance imaging; CT, computed tomography; PET, positron emission tomography; HER2, human epidermal growth factor receptor 2.

###### 

Sensitivity, specificity, PPV, and NPV for each preoperative image-modality when predicting involvement of three or more axillary lymph nodes

  Variable      Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ------------- ----------------- ----------------- --------- ---------
  Axillary US   66.7              88.4              43.2      95.3
  Chest CT      55.2              92.8              50.8      93.9
  PET-CT        70.7              74.5              27.2      94.9

PPV, positive predictive value; NPV, negative predictive value; US, ultrasonography; CT, computed tomography; PET, positron emission tomography.

###### 

Multivariate logistic regression analysis of factors associated with involvement of three or more ALNs

  Variable                             Odds ratio   95% CI      p-value
  ------------------------------------ ------------ ----------- ----------
  Age                                  0.99         0.97-1.00   0.097
  Tumor size by preoperative US (cm)   1.08         0.91-1.28   0.392
  Axillary US grade                    2.13         1.80-2.52   \< 0.001
  Chest CT ALN positive                4.78         3.07-7.45   \< 0.001

ALN, axillary lymph node; CI, confidence interval; US, ultrasonography; CT, computed tomography.
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